ClinicalTrials.gg
RecruitingNCT06034327EUCALYPTUSUpdated Dec 29, 2025

Efficacy in Controlling Myopia in Young Children Using a Novel Spectacle Lens

An interventional study of Single vision, impact-resistant spectacle lenses; Test Arm and Single vision, impact-resistant spectacle lenses; Control Arm in Myopia, Juvenile Myopia and Myopia Progression, sponsored by SightGlass Vision, Inc.. Recruiting at 14 sites in United States. Open to participants aged 6 Years to 8 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-29.

Sponsored by SightGlass Vision, Inc. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
6 Years to 8 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Myopia by SightGlass Vision, Inc. — 3 open to participants now, 12 under way, none of them phase 3. Myopia · SightGlass Vision, Inc..

Planned enrollment
6th of 14
150 · median 71
Started
2023
with 3 others
No phase
14 of 14
3 open now
Primary completion
2027-01
later than 9 of 11 live
Registered
11th of 14
by date

Among the 14 studies in Myopia by SightGlass Vision, Inc., this one is the 6th largest by planned enrollment, is one of 4 that started in 2023, is one of 14 with no phase, reaches primary completion later than 9 of the 11 other live ones, and was the 11th registered.

Myopia

1,165 studies on the registry are indexed under Myopia; 228 are open to participants now.

Browse Myopia studies →

Open to participants now

3 of the 14 studies in Myopia by SightGlass Vision, Inc. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 124 Myopia studies recruiting now, 20 (16%) set no upper age limit and 103 (83%) stop at 75 or younger; 85 take children under 18; 53 take healthy volunteers.

This study: 6 Years to 8 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Myopia by SightGlass Vision, Inc., or all of them as a file.
02

Study summary

This is a conventional efficacy trial to validate the results from previous clinical trials for younger children; the 12-month efficacy results will be used to predict the 3-year treatment efficacy.

This is a randomized, controlled (1:1), multisite, subject- and observer-masked, 2-arm parallel group study.

03

Conditions studied

  • Myopia
  • Juvenile Myopia
  • Myopia Progression

Browse trials for

04

Who can participate

Ages eligible
6 Years to 8 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Children 6 - 8 years of age (inclusive) at time of /assent;
  2. Spherical equivalent refractive error between -0.75 and -4.50 D inclusive (by manifest refraction) in each eye;
  3. Astigmatism if present, less than or equal to -1.25 DC (by manifest refraction) in each eye;
  4. Best corrected visual acuity by manifest refraction of +0.10 logMAR (20/25 Snellen equivalent) or better in each eye;
  5. The difference in spherical equivalent power between the two eyes (anisometropia based on manifest refraction) must be less than or equal to 1.50 D;
  6. Agree to wear the assigned spectacles constantly except for sleeping, swimming, or other activities in which spectacle wear would be dangerous or otherwise not possible (minimum of 10 hours per day);
  7. Ability to comply with study procedures, including high and low contrast visual acuity, axial length, and cycloplegic autorefraction measurements taken for both eyes at the baseline visit;
  8. Willingness to participate in the trial for 24 months without contact lens wear;
  9. The subject's parent(s) or legal guardian(s) must read, understand and sign the Statement of Informed Consent and receive a fully executed copy of the form.

Exclusion criteria

Exclusion Criteria:

  1. Subject has previously or currently wears contact lenses (greater than 1-month usage);
  2. Current or prior use of bifocals, progressive addition spectacle lenses
  3. Current or prior use of any myopia control treatment (e.g., atropine, multifocal contact lenses, orthokeratology);
  4. Amblyopia in either eye;
  5. Strabismus by cover test at far (4 m) or near (40 cm) wearing distance correction;
  6. Any ocular or systemic conditions that could influence refractive development or status [e.g., keratoconus, congenital glaucoma, ocular trauma, diabetes, Marfan syndrome or other connective tissue disorder, Down's syndrome, family history of poor night vision (to prevent against enrolling subjects with congenital stationary night blindness)];
  7. Known allergy to proparacaine, tetracaine, or tropicamide;
  8. Participation in any clinical study within 30 days of the Baseline visit;
  9. Subject's sibling or other household member is already enrolled in this trial.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Test Arm 1

    Single vision, impact-resistant spectacle lenses

    Device: Single vision, impact-resistant spectacle lenses; Test Arm

  • Other
    Test Arm 2

    Single vision, impact-resistant spectacle lenses

    Device: Single vision, impact-resistant spectacle lenses; Control Arm

Interventions

  • DeviceSingle vision, impact-resistant spectacle lenses; Test Arm

    Use of single vision, impact-resistant spectacle lenses may reduce the rate of progression of juvenile myopia

  • DeviceSingle vision, impact-resistant spectacle lenses; Control Arm

    Single vision, impact-resistant spectacle lenses

06

What researchers measure

Primary outcomes

  1. Spherical equivalent refraction

    Change in spherical equivalent refraction from baseline

    Time frame: 12 months

Secondary outcomes

  1. Axial length

    Change in axial length from baseline

    Time frame: 12 months

07

Study locations

14 of 14 sites recruiting
  • Elsa Pao, OD
    Oakland, California 94607, United States
    Recruiting
    • Vanessa Chen · Contact510-238-9797
    • Elsa Pao, OD · Principal investigator
  • Scripps Poway Eyecare
    San Diego, California 92131, United States
    Recruiting
    • Leslie Shan, OD · Contact858-530-2800
    • Keith Wan, OD · Principal investigator
  • Pacific Rims Optometry
    San Francisco, California 94127, United States
    Recruiting
    • Aileen Guzman · Contact415-655-3937
    • Selena Chan, OD · Principal investigator
  • Paje Optometric
    Santa Ana, California 92704, United States
    Recruiting
    • Daisy Magdaleno · Contact714-557-9492
    • Vanessa Grichine, OD · Principal investigator
  • Omega Vision Center
    Longwood, Florida 32779, United States
    Recruiting
    • Renee Warren · Contact407-869-4733
    • Christopher Pearson, OD · Principal investigator
  • Marietta Eye Clinic
    Marietta, Georgia 30060, United States
    Recruiting
    • Doreatha Kennerly · Contact678-803-2600
    • Monica Bratton, MD · Principal investigator
  • Ilinois College of Optometry
    Chicago, Illinois 60616, United States
    Recruiting
    • Jessica Martinez · Contact312-949-7000
    • Yi Pang, OD · Principal investigator
  • Kannarr Eye Care
    Pittsburg, Kansas 66762, United States
    Recruiting
    • Megan Compton, RN · Contact620-235-1737
    • Shane Kannarr, OD · Principal investigator
  • New England College of Optometry
    Boston, Massachusetts 02115, United States
    Recruiting
    • Lilly Cheam · Contact617-266-2030
    • Katherine Green, OD · Principal investigator
  • Advanced Eyecare PC
    Raytown, Missouri 64133, United States
    Recruiting
    • Tamara Urias · Contact816-353-1872
    • Richard Wilson, OD · Principal investigator
  • Athens Eye Care
    Athens, Ohio 45701, United States
    Recruiting
    • Jen Brite · Contact740-594-2271
    • Shane Foster, OD · Contact
    • Shane Foster, OD · Principal investigator
  • Procare Vision Centers, Inc.
    Granville, Ohio 43023, United States
    Recruiting
    • Katherine Bickle, OD · Contact
    • Katherine Bickle, OD · Principal investigator
  • Texas State Optical - Dowlen
    Beaumont, Texas 77706, United States
    Recruiting
    • Bobbie Hampton · Contact409-899-9999
    • Samir Patel, OD · Principal investigator
  • Bellaire Family Eye Care
    Bellaire, Texas 77401, United States
    Recruiting
    • Ashley Tucker, OD · Contact
    • Ashley Tucker, OD · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Jan 2027, 40 months after the start.

Of 236 industry-sponsored interventional studies with no phase under Myopia, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 24. This study's planned 40 months is above that.

Counting every sponsor, half of 438 studies reached it within 14 months; a quarter within 3 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2023
First posted
Sep 13, 2023
StartActual
Sep 18, 2023
Primary completionEst.
Jan 31, 2027
CompletionEst.
Mar 31, 2027
Last update
Dec 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06034327
Lead sponsor
SightGlass Vision, Inc.
Responsible party
Sponsor
First posted
Sep 13, 2023
Start date
Sep 18, 2023
Primary completion
Jan 31, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Dec 29, 2025

Study contacts

Jennifer S Hill, BS
Contact
jhill@sightglassvision.com
678-361-4877
Vanessa Tasso, MA, MBA
Contact
vtasso@sightglassvision.com
949-751-7039

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion